Literature DB >> 26163274

Current Developments and Future Prospects for Plant-Made Biopharmaceuticals Against Rabies.

Sergio Rosales-Mendoza1.   

Abstract

Rabies is a prevalent health problem in developing countries. Although vaccines and immunoglobulin treatments are available, their cost and multiple-dose treatments restrict availability. During the last two decades, plants have served as a low-cost platform for biopharmaceuticals production and have been applied to fight against rabies during the last two decades. Herein, I provide a description of the state of the art in the development of plant-made pharmaceuticals against rabies and identify key prospects for the field in terms of novel strategies, immunogen design, and therapeutic antibodies production.

Mesh:

Substances:

Year:  2015        PMID: 26163274     DOI: 10.1007/s12033-015-9880-3

Source DB:  PubMed          Journal:  Mol Biotechnol        ISSN: 1073-6085            Impact factor:   2.695


  75 in total

1.  A Phase 3, multicenter, open-label, switchover trial to assess the safety and efficacy of taliglucerase alfa, a plant cell-expressed recombinant human glucocerebrosidase, in adult and pediatric patients with Gaucher disease previously treated with imiglucerase.

Authors:  Gregory M Pastores; Milan Petakov; Pilar Giraldo; Hanna Rosenbaum; Jeffrey Szer; Patrick B Deegan; Dominick J Amato; Eugen Mengel; Ee Shien Tan; Raul Chertkoff; Einat Brill-Almon; Ari Zimran
Journal:  Blood Cells Mol Dis       Date:  2014-06-18       Impact factor: 3.039

2.  Studies on the structures and antigenic properties of rabies virus glycoprotein analogues produced in yeast cells.

Authors:  S Sakamoto; T Ide; S Tokiyoshi; J Nakao; F Hamada; M Yamamoto; J A Grosby; Y Ni; A Kawai
Journal:  Vaccine       Date:  1999-01-21       Impact factor: 3.641

Review 3.  Transgenic plants: a 5-year update on oral antipathogen vaccine development.

Authors:  Marisela Hernández; Gabriela Rosas; Jacquelynne Cervantes; Gladis Fragoso; Sergio Rosales-Mendoza; Edda Sciutto
Journal:  Expert Rev Vaccines       Date:  2014-08-27       Impact factor: 5.217

Review 4.  Current rabies vaccines and prophylaxis schedules: preventing rabies before and after exposure.

Authors:  M J Warrell
Journal:  Travel Med Infect Dis       Date:  2012-02-17       Impact factor: 6.211

5.  Antigens produced in plants by infection with chimeric plant viruses immunize against rabies virus and HIV-1.

Authors:  V Yusibov; A Modelska; K Steplewski; M Agadjanyan; D Weiner; D C Hooper; H Koprowski
Journal:  Proc Natl Acad Sci U S A       Date:  1997-05-27       Impact factor: 11.205

6.  Generation of glyco-engineered Nicotiana benthamiana for the production of monoclonal antibodies with a homogeneous human-like N-glycan structure.

Authors:  Richard Strasser; Johannes Stadlmann; Matthias Schähs; Gabriela Stiegler; Heribert Quendler; Lukas Mach; Josef Glössl; Koen Weterings; Martin Pabst; Herta Steinkellner
Journal:  Plant Biotechnol J       Date:  2008-03-13       Impact factor: 9.803

7.  N-glycosylation engineering of plants for the biosynthesis of glycoproteins with bisected and branched complex N-glycans.

Authors:  Alexandra Castilho; Pia Gattinger; Josephine Grass; Jakub Jez; Martin Pabst; Friedrich Altmann; Markus Gorfer; Richard Strasser; Herta Steinkellner
Journal:  Glycobiology       Date:  2011-02-11       Impact factor: 4.313

Review 8.  Plant-based vaccines against viruses.

Authors:  Edward P Rybicki
Journal:  Virol J       Date:  2014-12-03       Impact factor: 4.099

9.  Novel vaccines to human rabies.

Authors:  Hildegund C J Ertl
Journal:  PLoS Negl Trop Dis       Date:  2009-09-29

10.  Low cost tuberculosis vaccine antigens in capsules: expression in chloroplasts, bio-encapsulation, stability and functional evaluation in vitro.

Authors:  Priya Saikumar Lakshmi; Dheeraj Verma; Xiangdong Yang; Bethany Lloyd; Henry Daniell
Journal:  PLoS One       Date:  2013-01-23       Impact factor: 3.240

View more
  1 in total

1.  Enhanced transport of plant-produced rabies single-chain antibody-RVG peptide fusion protein across an in cellulo blood-brain barrier device.

Authors:  Waranyoo Phoolcharoen; Christophe Prehaud; Craig J van Dolleweerd; Leonard Both; Anaelle da Costa; Monique Lafon; Julian K-C Ma
Journal:  Plant Biotechnol J       Date:  2017-04-19       Impact factor: 9.803

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.